Researchers develop potential treatment for fatal, incurable kidney disease

By Al Saint Jacques, MDLinx
Published February 22, 2017

Key Takeaways

Researchers have developed a potential drug to treat polycystic kidney disease, an incurable genetic disease that often leads to end-stage kidney failure, according to a study describing research that led to the drug’s development, published online in the February issue the journal Nature Communications.

The drug, called RGLS4326, is in preclinical animal testing at San Diego-based Regulus Therapeutics Inc. An investigational new drug filing to pave the way for human clinical trials is expected later this year, according to senior author Dr. Vishal Patel, Assistant Professor of Internal Medicine at UT Southwestern, Dallas, TX.

Autosomal dominant polycystic kidney disease (ADPKD), which affects about 600,000 people in the US, causes numerous fluid-filled cysts to form in the kidney. An affected kidney, normally the size of a human fist, sometimes grows as large as a football. As their numbers and sizes increase, these cysts eventually interfere with the kidney’s ability to filter blood and remove bodily waste. The cysts can quietly grow for decades until symptoms appear such as blood in the urine, Dr. Patel said. About half of those affected with ADPKD suffer kidney failure by age 60, according to the National Kidney Foundation.

“There isn’t a single drug on the US market right now to treat the disease,” Dr. Patel said. “Once your kidneys fail, your only option for survival is to get a transplant or start dialysis.”

In 2009, Dr. Patel began searching for microRNAs that might underlie progression of ADPKD. MicroRNAs – or MiRs for short – are tiny RNA fragments that interfere with normal gene expression.

Proof that such RNA fragments even existed came in the early 1990s; their presence in humans was first reported in 2000. Those discoveries led to a groundswell of interest in developing drugs to treat diseases caused by microRNAs, in part because the process can be straightforward once the problem-causing fragment is identified, Dr. Patel explained.

“Because miRs are so small, drugs can easily be designed against them. And since we know the nucleotide sequence of every known microRNA, all that is required is to prepare an anti-miR with a sequence that is exactly the opposite of the miR’s,” he said.

In this study, researchers in Dr. Patel’s lab focused on microRNA cluster 17~92 following identification of potential miR targets. A National Institutes of Health grant funded the UT Southwestern research. In 2013, Dr. Patel and fellow researchers reported in Proceedings of the National Academy of Sciences that this microRNA cluster indeed appeared to promote kidney cyst growth.

Using four mouse models, the researchers next studied whether inhibiting this microRNA could slow cyst growth and thus delay ADPKD progression. They found that genetically deleting microRNA-17~92 slowed cyst growth and more than doubled the life spans of some mice tested.

Based on this information, Dr. Patel’s lab collaborated with Regulus Therapeutics to test an anti-microRNA-17 drug. The test drug was found to slow the growth of kidney cysts in two mouse models and in cell cultures of human kidney cysts, the study showed.

In the Nature Communications study, UT Southwestern researchers also reported how miR-17 causes cyst proliferation: the molecule essentially reprograms the metabolism of kidney cells so that cellular structures called mitochondria use less nutrients, freeing up resources to instead make cell parts that become cysts. MiR-17 accomplishes this by repressing a protein involved in making RNA called peroxisome proliferator-activated receptor alpha (PPARα), the researchers found.

Other UT Southwestern researchers included lead author Dr. Sachin Hajarnis, a research scientist; Dr. Ronak Lakhia, Instructor in Internal Medicine; Matanel Yheskel and Andrea Flaten, research technicians; Darren Williams, former research associate; Dr. Shanrong Zhang, research engineer; Joshua Johnson, an MD/PhD student; Dr. William Holland and Dr. Christine Kusminski, Assistant Professors of Internal Medicine; and Dr. Philipp Scherer, Professor of Internal Medicine and Cell Biology, who holds the Gifford O. Touchstone, Jr. and Randolph G. Touchstone Distinguished Chair in Diabetes Research.

Also contributing to the study were researchers from the University of Minnesota Medical School, the Mayo Clinic School of Medicine, the University of Montreal, the University of Kansas, and Regulus Therapeutics.

UT Southwestern and Regulus Therapeutics have applied for a patent for treatment of polycystic kidney disease with miR-17 inhibitors. In addition, Dr. Patel’s laboratory has a sponsored research agreement with Regulus, and Dr. Patel serves as a consultant for Regulus.

Funding was provided by the National Institutes of Health (NIH) and the PKD Foundation. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH under Award Number R01DK102572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Share with emailShare to FacebookShare to LinkedInShare to Twitter